Croatia's Optimapharm acquires MKS Research
Croatia's Optimapharm, a clinical research organisation, has acquired Czech peer MKS Research for an undisclosed price.
The move is in line with Optimapharm’s medium-term strategic objective of becoming the largest independent clinical research organization in CEE, with business operations across Europe and the U.S.
"The clinical research market is experiencing a continued rise, and we have the knowhow, references and strong financial position enabling us to lead the consolidation in the region", said Optimapharm CEO Gordana Greguric Cicak.
By consolidating MKS Research, Optimapharm will have a total of 120 full-time employees and annual revenues over EUR 12 million. The company plans to double its revenues over the next three years, and continue acquiring good-quality companies.